schizophrenia
Conditions
Interventions
Aripiprazole once-monthly will be maintained at the same dose as baseline for 52 weeks.
Brexpiprazole will be augmented with aripiprazole once-monthly for 52 weeks
Sponsors
Department of Neuropsychiatry, Kansai Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Outpatients having a diagnose of schizophrenia or schizoaffective disorder according to ICD-10 Patients who have not been hospitalized in a psychiatric unit in the past 6 months Baseline total score 120 or less on the PANSS total score Having regularly and consecutively received aripiprazole once-monthly for at least 2 months Having provided written informed consent
Exclusion criteria
Exclusion criteria: Serious complication Active suicidal ideations or past suicide attempts Drug or alcohol abuse Pregnant or breast-feeding females mental retardation Using of oral aripiprazole or asenapine, blonanserin Having been judged as unsuitable for the study forin other reasons by an principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Social Functioning Scale (SFS) from week 0 to week 52 | — |
Secondary
| Measure | Time frame |
|---|---|
| Remission rate, Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity scale (CGI-S), Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS), UKU Side Effect Scale(UKU), Barnes Akathisia Rating Scale (BARS), Epworth Sleepness Scale(ESS), body weight, Body Mass Index, blood biochemistry, Japanese Adult Reading Test (JART), electroencephalography, Brief Assessment of Cognition in Schizophrenia (BACS), Social Cognition. Screening Questionnaire (SCSQ), Japanese version of the Questionnaire about the Process of Recovery (QPR-J), Subjective well-being under neuroleptic drug treatment short form, Japanese version (SWNS-J) | — |
Countries
Japan
Contacts
Public ContactYoshiteru Takekita
Kansai Medical University Department of Neuropsychiatry
Outcome results
None listed